Published in Curr Opin Pharmacol on February 01, 2005
Drug use related problems among nonmedical users of prescription stimulants: a web-based survey of college students from a Midwestern university. Drug Alcohol Depend (2007) 1.62
Thalamo-cortical dysfunction in cocaine abusers: implications in attention and perception. Psychiatry Res (2007) 1.44
Methylphenidate disrupts social play behavior in adolescent rats. Neuropsychopharmacology (2008) 1.25
Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats. Psychopharmacology (Berl) (2011) 1.14
Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 1.08
Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther (2008) 1.06
Impaired neurocognitive functions affect social learning processes in oppositional defiant disorder and conduct disorder: implications for interventions. Clin Child Fam Psychol Rev (2012) 0.93
Influence of methylphenidate on brain development--an update of recent animal experiments. Behav Brain Funct (2006) 0.91
Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models. Br J Pharmacol (2014) 0.90
Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat (2008) 0.90
Total Synthesis (+)-7-Bromotrypargine and Unnatural Analogs: Biological Evaluation Uncovers Activity at CNS Targets of Therapeutic Relevance. ACS Chem Neurosci (2011) 0.89
Animal model of methylphenidate's long-term memory-enhancing effects. Learn Mem (2014) 0.83
Reduction of impulsivity with amphetamine in an appetitive fixed consecutive number schedule with cue for optimal performance in rats. Psychopharmacology (Berl) (2007) 0.82
Recent progress in neuroactive marine natural products. Nat Prod Rep (2014) 0.81
What have positron emission tomography and 'Zippy' told us about the neuropharmacology of drug addiction? Br J Pharmacol (2011) 0.81
Substance use disorders in children and adolescents with attention-deficit/hyperactivity disorder: implications for treatment and the role of the primary care physician. Prim Care Companion J Clin Psychiatry (2008) 0.80
Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder. Neuroimage Clin (2013) 0.80
Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat (2008) 0.78
Abnormal behaviors and microstructural changes in white matter of juvenile mice repeatedly exposed to amphetamine. Schizophr Res Treatment (2011) 0.77
Prenatal exposure to methylphenidate affects the dopamine system and the reactivity to natural reward in adulthood in rats. Int J Neuropsychopharmacol (2014) 0.75
Amphetamine withdrawal differentially affects hippocampal and peripheral corticosterone levels in response to stress. Brain Res (2016) 0.75
Environmental enrichment has no effect on the development of dopaminergic and GABAergic fibers during methylphenidate treatment of early traumatized gerbils. J Negat Results Biomed (2008) 0.75
Psychopharmacology of ADHD in pediatrics: current advances and issues. Neuropsychiatr Dis Treat (2009) 0.75
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2005) 1.88
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol (2008) 1.80
Role of GABA in anxiety and depression. Depress Anxiety (2007) 1.79
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A (2012) 1.79
The size, burden and cost of disorders of the brain in the UK. J Psychopharmacol (2013) 1.62
Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry (2005) 1.62
GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev (2012) 1.61
Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis (2008) 1.59
A tale of two Es. J Psychopharmacol (2006) 1.53
Substitution therapy for alcoholism: time for a reappraisal? J Psychopharmacol (2011) 1.47
MDMA, politics and medical research: have we thrown the baby out with the bathwater? J Psychopharmacol (2007) 1.42
Dopamine and social anxiety disorder. Rev Bras Psiquiatr (2006) 1.38
Prescribing antidepressants post Cipriani et al. J Psychopharmacol (2009) 1.37
Human taste thresholds are modulated by serotonin and noradrenaline. J Neurosci (2006) 1.36
Psychotropic drugs, cardiac arrhythmia, and sudden death. J Clin Psychopharmacol (2003) 1.36
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.36
Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med (2006) 1.25
Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol (2013) 1.22
Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol (2014) 1.22
Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry (2009) 1.20
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Association of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumption. Neuropsychopharmacology (2010) 1.16
The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse (2007) 1.15
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry Res (2003) 1.13
Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity. Neuroimage (2012) 1.13
Functional connectivity analysis of the neural circuits of opiate craving: "more" rather than "different"? Neuroimage (2003) 1.10
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
Effects of acute tyrosine/phenylalanine depletion on the selective processing of smoking-related cues and the relative value of cigarettes in smokers. Psychopharmacology (Berl) (2007) 1.10
Cape Town consensus on posttraumatic stress disorder. CNS Spectr (2009) 1.09
Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety (2005) 1.09
Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry (2004) 1.08
Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry (2006) 1.08
Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol (2007) 1.07
Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci (2013) 1.07
WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr (2003) 1.06
Harms associated with psychoactive substances: findings of the UK National Drug Survey. J Psychopharmacol (2009) 1.05
Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry (2008) 1.04
Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol (2005) 1.03
Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophr Bull (2012) 1.03
Is there cognitive impairment in clinically 'healthy' abstinent alcohol dependence? Alcohol Alcohol (2005) 1.01
Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol (2013) 1.00
GABAB receptors in addiction and its treatment. Adv Pharmacol (2010) 1.00
Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. J Neurosci (2004) 0.99
In vitro and ex vivo distribution of [3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology (2005) 0.99
Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. J Psychopharmacol (2011) 0.98
Endogenous opioid release in the human brain reward system induced by acute amphetamine administration. Biol Psychiatry (2012) 0.98
Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. Hum Psychopharmacol (2013) 0.98
Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol (2009) 0.97
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse (2011) 0.95
No psychiatry without psychopharmacology. Br J Psychiatry (2011) 0.95
Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab (2002) 0.95
Acute tryptophan depletion. Part I: rationale and methodology. Aust N Z J Psychiatry (2005) 0.95
Significant decreases in frontal and temporal [11C]-raclopride binding after THC challenge. Neuroimage (2010) 0.94
Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol (2009) 0.93
Cytokine levels in euthymic bipolar patients. J Affect Disord (2010) 0.93
Foresight brain science, addiction and drugs project. J Psychopharmacol (2005) 0.93
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. J Psychopharmacol (2006) 0.93
A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology (2013) 0.92
Benzodiazepines: risks and benefits. A reconsideration. J Psychopharmacol (2013) 0.91
Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol (2003) 0.90
Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology (2005) 0.90
History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol (2011) 0.90
Gender differences in brain serotonin transporter availability in panic disorder. J Psychopharmacol (2010) 0.89
Brain imaging studies in human addicts. Eur Neuropsychopharmacol (2003) 0.89
Clinical relevance of as-needed treatment with nalmefene in alcohol-dependent patients. Eur Addict Res (2015) 0.89
Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder. Biol Psychiatry (2004) 0.87
WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr (2003) 0.87
Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res (2009) 0.86
Personalized risk assessment of drug-related harm is associated with health outcomes. PLoS One (2013) 0.85
Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) (2003) 0.85
Elevating endogenous GABA levels with GAT-1 blockade modulates evoked but not induced responses in human visual cortex. Neuropsychopharmacology (2013) 0.85
A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. Psychopharmacology (Berl) (2007) 0.85
Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. Behav Brain Res (2012) 0.84
The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability. J Psychopharmacol (2010) 0.84
Mechanism of action of antidepressants. Psychopharmacol Bull (2002) 0.84
Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder. Psychopharmacology (Berl) (2009) 0.84
Naloxone displacement at opioid receptor sites measured in vivo in the human brain. Eur J Pharmacol (2003) 0.84
Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther (2004) 0.83
The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol (2012) 0.83
Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology (2002) 0.83
Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem (2006) 0.82
A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions. J Psychopharmacol (2010) 0.82
Sleep and its disorders in translational medicine. J Psychopharmacol (2011) 0.82
Imaging alcohol cue exposure in alcohol dependence using a PET 15O-H2O paradigm: results from a pilot study. Addict Biol (2006) 0.82
Low sensitivity of the positron emission tomography ligand [11C]diprenorphine to agonist opiates. J Pharmacol Exp Ther (2007) 0.81
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology (2003) 0.81
GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. Eur Neuropsychopharmacol (2011) 0.81
Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol (2002) 0.81
Brain dopamine response in human opioid addiction. Br J Psychiatry (2008) 0.81
The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol (2005) 0.81
Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol (2012) 0.81
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. J Sleep Res (2009) 0.81
Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ (2004) 0.81
Depleting serotonin enhances both cardiovascular and psychological stress reactivity in recovered patients with anxiety disorders. J Clin Psychopharmacol (2006) 0.80
N1'-fluoroethyl-naltrindole (BU97001) and N1'-fluoroethyl-(14-formylamino)-naltrindole (BU97018) potential delta-opioid receptor PET ligands. Nucl Med Biol (2002) 0.80
Reduced thalamic grey matter volume in opioid dependence is influenced by degree of alcohol use: a voxel-based morphometry study. J Psychopharmacol (2008) 0.80
Popular intoxicants: what lessons can be learned from the last 40 years of alcohol and cannabis regulation? J Psychopharmacol (2011) 0.80
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr (2003) 0.80
Increased sympathetic response to standing in panic disorder. Psychiatry Res (2003) 0.80
Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol (2009) 0.80